Welcome to our dedicated page for Sera Prognostics news (Ticker: SERA), a resource for investors and traders seeking the latest updates and insights on Sera Prognostics stock.
Sera Prognostics, Inc. (NASDAQ: SERA) is a health diagnostics company headquartered in Salt Lake City, Utah, focused on precision pregnancy care and the early prediction of spontaneous preterm birth. News about Sera often centers on its PreTRM® Test, a blood-based biomarker test that provides individualized risk prediction for preterm birth in asymptomatic singleton pregnancies, and on the growing clinical and payer interest in this approach.
On this page, readers can find updates on Sera’s clinical research, including results and publications from the Prematurity Risk Assessment Combined With Clinical Interventions for Improving Neonatal outcoMEs (PRIME) study. Company press releases describe how the PRIME randomized controlled trial evaluated the PreTRM Test combined with targeted interventions and reported reductions in very early preterm births, NICU admissions, neonatal complications, and NICU length of stay compared with standard care.
SERA news coverage also includes quarterly financial results, payer and Medicaid pilot initiatives, and commentary on commercial progress for the PreTRM Test. The company has highlighted engagement with Medicaid plans and other organizations in multiple states, as well as presentations at medical and investor conferences where leadership discusses clinical data, health economic analyses, and market adoption efforts.
Investors and healthcare professionals following SERA can use this news feed to review announcements related to leadership appointments, conference presentations, regulatory filings summarized in press releases, and ongoing work to position pregnancy biomarker testing within prenatal care. Bookmark this page to access a consolidated view of Sera Prognostics’ latest press releases, study milestones, and business updates connected to its focus on improving outcomes for mothers and newborns.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.